CD274 and neoplasm: Although the high-risk group shows lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis, they are more sensitive to immune therapy with anti-PD1 and anti-CTLA-4, while the low-risk group responds better to immune therapy with anti-PD-L1 [44].